Arvinas announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has been appointed to join. Cunningham currently serves as Chief Commercial Officer at Exact Sciences and was previously President & CEO of GE Healthcare’s U.S. & Canada regions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas Announces Changes to its Board of Directors
- Arvinas price target lowered to $72 from $88 at Citi
- Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update